CA2438596C - Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders - Google Patents

Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders Download PDF

Info

Publication number
CA2438596C
CA2438596C CA002438596A CA2438596A CA2438596C CA 2438596 C CA2438596 C CA 2438596C CA 002438596 A CA002438596 A CA 002438596A CA 2438596 A CA2438596 A CA 2438596A CA 2438596 C CA2438596 C CA 2438596C
Authority
CA
Canada
Prior art keywords
methyl
pyrazino
indole
tetrahydro
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002438596A
Other languages
English (en)
French (fr)
Other versions
CA2438596A1 (en
Inventor
Paul Hebeisen
Patrizio Mattei
Marc Muller
Hans Richter
Stephan Roever
Sven Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Ligand UK Research Ltd
Original Assignee
F Hoffmann La Roche AG
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Vernalis Research Ltd filed Critical F Hoffmann La Roche AG
Publication of CA2438596A1 publication Critical patent/CA2438596A1/en
Application granted granted Critical
Publication of CA2438596C publication Critical patent/CA2438596C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002438596A 2001-03-13 2002-03-06 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders Expired - Fee Related CA2438596C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0106177.9A GB0106177D0 (en) 2001-03-13 2001-03-13 Piperazine derivatives
GB0106177.9 2001-03-13
PCT/EP2002/002443 WO2002072584A2 (en) 2001-03-13 2002-03-06 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders

Publications (2)

Publication Number Publication Date
CA2438596A1 CA2438596A1 (en) 2002-09-19
CA2438596C true CA2438596C (en) 2008-07-08

Family

ID=9910578

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002438596A Expired - Fee Related CA2438596C (en) 2001-03-13 2002-03-06 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders

Country Status (20)

Country Link
US (1) US6844345B2 (enExample)
EP (1) EP1370561B1 (enExample)
JP (1) JP4230225B2 (enExample)
KR (1) KR100618748B1 (enExample)
CN (1) CN1245405C (enExample)
AR (1) AR035945A1 (enExample)
AT (1) ATE422498T1 (enExample)
AU (1) AU2002304833B2 (enExample)
BR (1) BR0208111A (enExample)
CA (1) CA2438596C (enExample)
DE (1) DE60231107D1 (enExample)
ES (1) ES2320739T3 (enExample)
GB (1) GB0106177D0 (enExample)
GT (1) GT200200048A (enExample)
MX (1) MXPA03008338A (enExample)
PA (1) PA8540801A1 (enExample)
PE (1) PE20021043A1 (enExample)
UY (1) UY27204A1 (enExample)
WO (1) WO2002072584A2 (enExample)
ZA (1) ZA200306613B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762132B1 (en) * 2000-08-31 2004-07-13 Micron Technology, Inc. Compositions for dissolution of low-K dielectric films, and methods of use
BR0311970A (pt) 2002-06-19 2005-03-29 Biovitrum Ab Novos compostos, seu uso e preparação
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
ATE525354T1 (de) * 2004-05-03 2011-10-15 Janssen Pharmaceutica Nv Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
US7622466B2 (en) * 2005-11-18 2009-11-24 Hoffman-La Roche Inc. Azaindole-2-carboxamide derivatives
ES2333672T3 (es) 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
EP2254886B1 (en) * 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
US20130143812A1 (en) * 2010-05-27 2013-06-06 Sekisui Medical Co., Ltd. Anti-inflammatory drug
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
SG11201405328SA (en) 2012-03-16 2014-11-27 Vitae Pharmaceuticals Inc Liver x receptor modulators
ES2607113T3 (es) 2012-03-16 2017-03-29 Vitae Pharmaceuticals, Inc. Moduladores de los receptores X del hígado
CA2880682A1 (en) * 2012-08-06 2014-02-13 F. Hoffmann-La Roche Ag Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
EP2981538B1 (en) * 2013-04-02 2017-08-02 F. Hoffmann-La Roche AG Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN106317058B (zh) * 2016-08-17 2018-10-02 广东省微生物研究所 化合物dichotocejpin A及其制备方法和在制备治疗糖尿病药物中的应用
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN117586171A (zh) * 2022-08-12 2024-02-23 长春金赛药业有限责任公司 吲哚类衍生物、药物组合物及其在中枢神经领域的应用
WO2026006356A1 (en) * 2024-06-25 2026-01-02 Vanderbilt University 6-(pyrimidin-5-yl)-3,4-dihydropyrazino[l,2-a]imdol-l(2h)-one mcl-1 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317524A (en) 1965-02-04 1967-05-02 American Home Prod Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
EP0572863A1 (de) * 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
AU3831495A (en) * 1994-10-20 1996-05-15 American Home Products Corporation Indole derivatives useful as serotonergic agents
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
WO2002010169A1 (en) * 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives

Also Published As

Publication number Publication date
KR100618748B1 (ko) 2006-08-31
GB0106177D0 (en) 2001-05-02
GT200200048A (es) 2002-11-15
DE60231107D1 (de) 2009-03-26
KR20030080255A (ko) 2003-10-11
AR035945A1 (es) 2004-07-28
ZA200306613B (en) 2004-11-25
WO2002072584A3 (en) 2003-01-03
CN1245405C (zh) 2006-03-15
EP1370561A2 (en) 2003-12-17
PE20021043A1 (es) 2002-11-19
JP2004532823A (ja) 2004-10-28
ATE422498T1 (de) 2009-02-15
US6844345B2 (en) 2005-01-18
MXPA03008338A (es) 2003-12-11
BR0208111A (pt) 2004-03-02
JP4230225B2 (ja) 2009-02-25
UY27204A1 (es) 2002-09-30
PA8540801A1 (es) 2005-02-04
CA2438596A1 (en) 2002-09-19
WO2002072584A2 (en) 2002-09-19
CN1529706A (zh) 2004-09-15
AU2002304833B2 (en) 2006-05-04
US20020169163A1 (en) 2002-11-14
EP1370561B1 (en) 2009-02-11
ES2320739T3 (es) 2009-05-28

Similar Documents

Publication Publication Date Title
US6844345B2 (en) Piperazine derivatives
US6933387B2 (en) Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles
CA2432085C (en) Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
US6583134B2 (en) Aza- indolyl derivatives for treating obesity
CN100334076C (zh) 二氢吲哚衍生物及其作为5－ht2受体配体的用途
AU2002304833A1 (en) Tetrahydro-pyrazino (1,2-A) indoles for the treatment of central nervous disorders
AU2001240670A1 (en) New aza-indolyl derivatives
CA2530308C (en) 5ht2c receptor agonists for the treatment of diabetes and obesity
WO2000044753A1 (en) Pirazino(aza)indole derivatives
AU2001283955A1 (en) Piperazine derivatives
KR20040077885A (ko) 아자-아릴피페라진

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed